Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17300185 | 0.78 | GABRR1 (0.41) | ATMMAPTMCL1LMNAGABRR1 | |
| SCHEMBL9947548 | 0.78 | GABRR1 (0.41) | ATMMAPTMCL1LMNAGABRR1 | |
| SCHEMBL19352706 | 0.78 | GABRR1 (0.41) | ATMMAPTMCL1LMNAGABRR1 | |
| SCHEMBL23873825 | 0.77 | MEN1 (0.39) | LMNAGABRR1 | |
| SCHEMBL27370003 | 0.74 | PSMB5 (0.31) | — | |
| SCHEMBL7078228 | 0.73 | SMN1; SMN2 (0.52) | ATMMAPTMCL1LMNA | |
| SCHEMBL7078226 | 0.73 | SMN1; SMN2 (0.52) | ATMMAPTMCL1LMNA | |
| SCHEMBL7078225 | 0.73 | SMN1; SMN2 (0.52) | ATMMAPTMCL1LMNA | |
| SCHEMBL8368782 | 0.71 | SLC7A5 (0.50) | — | |
| SCHEMBL13931455 | 0.71 | RNPEP (0.44) | ATMMAPTMCL1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11766481-B2 | Glycan modified short interfering RNA | GANNA BIO, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20220387607-A1 | GLYCAN MODIFIED NUCLEIC ACIDS, METHODS OF PREPARATION, AND THERAPEUTIC USES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11766481-B2 | Glycan modified short interfering RNA | SNRPE, FUT6, ALG8 | ATM 2468/4885MAPT 4586/4885MCL1 4034/4885 |
| US-20220387607-A1 | GLYCAN MODIFIED NUCLEIC ACIDS, METHODS OF PREPARATION, AND THERAPEUTIC USES | NSUN3, RNGTT, SIGLEC7 | ATM 3219/4885MAPT 4153/4885MCL1 2319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.